Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
about
Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapyGenetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteinsHeat shock protein 90 targeting therapy: state of the art and future perspectiveHSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsHsp90: A New Player in DNA Repair?Maximizing the Therapeutic Potential of HSP90 InhibitorsNAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinonesAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersHeat-shock Protein 90 Is Essential for Stabilization of the Hepatitis C Virus Nonstructural Protein NS3Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.MET molecular mechanisms and therapies in lung cancerGeldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperonesGeldanamycin-induced osteosarcoma cell death is associated with hyperacetylation and loss of mitochondrial pool of heat shock protein 60 (hsp60)Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell LinesLow intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG.Geldanamycin induces production of heat shock protein 70 and partially attenuates ototoxicity caused by gentamicin in the organ of Corti explantsDevelopment and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.Combinatorial biosynthesis--potential and problems.Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsDevelopment and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaHeat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin.The role of lysosomes in limiting drug toxicity in mice.Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.Insights into the biosynthesis of the benzoquinone ansamycins geldanamycin and herbimycin, obtained by gene sequencing and disruption.A trans-activation domain in yeast heat shock transcription factor is essential for cell cycle progression during stress.Thermo-targeted drug delivery of geldanamycin to hyperthermic tumor margins with diblock elastin-based biopolymers.Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinHsp70 and its molecular role in nervous system diseasesHeat shock protein 70 upregulation by geldanamycin reduces brain injury in a mouse model of intracerebral hemorrhage.Molecular chaperone Hsp90 is important for vaccinia virus growth in cellsMEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.Induced protein degradation: an emerging drug discovery paradigm.Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
P2860
Q24337770-589E683D-171A-40D4-AD68-CC0BE1366AC7Q24522482-444FF9F7-9FEC-4351-B89E-0F787DA75294Q26776302-E5236D37-31B4-4FCF-8E9D-0C869E65B069Q26778548-9723802B-EA04-4091-8C80-DBCB9A78D961Q26778944-130B63FE-8999-4758-AACE-3DA18096C09EQ26798318-8DDDCC1C-0E65-4990-9181-865712F738C3Q26823209-2995B0D2-F8C5-478B-B022-A16929F34209Q27022514-61925BF4-2EBE-4359-A4DA-C05E1619003BQ27488153-3F9C7DC0-F4FE-4BFE-AC91-5E355C085F3EQ27676888-475CAC6D-9042-475A-8EBA-DCAC104632C3Q27853065-CCD91DBF-6BA2-4AC3-B8F9-401ECFA7A6CAQ28272688-C2DE245A-1FA5-4FF0-8EC3-43A7954F9B01Q28361532-2CF554C9-3074-4421-82B8-0825B85A2599Q28535817-96AEC793-21BD-4334-A604-4EFEE8594449Q28550872-F204AD85-1625-4BCA-80A8-80E8EBA669FCQ30420792-4B80CC62-D3DC-4223-8515-5D2256EE91A3Q30486570-2509FDA4-3B6B-4F32-A2D3-97BCF77A879AQ31039889-D35B1601-8D64-4FC5-B6D1-683C867BA504Q33231690-58A4B2DB-CD67-4A50-B723-B5A8110B2897Q33387877-3E6DD400-50AD-47A4-9E87-0275A5A84463Q33440318-1D5842B6-9C50-41EF-A717-826857E13166Q33577386-67BA26F6-120A-4490-B18D-6FA8BC5B3604Q33584583-ABF04354-853D-4BD1-A3DB-D31B3D519809Q33750795-3F6FABAE-DA81-4D49-810F-55B2197F4A6BQ33755217-F0357B6C-6C10-4985-94FC-997CB75EF9E2Q33789416-9F7616FD-BCE3-4788-87F1-2DBFBC0054CBQ33817522-EF3707E1-BEFB-4078-A1CA-FB5E1C39F2A8Q33823621-0D6B25AC-8D01-4877-85C5-3C94705B4427Q33836864-F5BE07B4-BB18-4212-A011-62BDF7DDC6BCQ33890864-F351E0A4-9DBC-478B-9B4D-7712DEEB0F10Q33913477-28049CD4-23F4-4421-A69E-CBFD43475726Q33957138-7FD873BB-8384-45B2-9501-0E9F8CE5B58DQ33994250-E4214642-D5DC-4B3C-84B0-D822CBCA81D8Q34018372-FBB19C2C-4712-409A-937E-827A391F1A8BQ34170760-2D0D29E9-E570-4336-AB44-6069294E1EDDQ34248112-BA209990-D0E0-4698-92F1-3C5D68590B1BQ34330496-C3CF9667-B3A7-4986-A224-DDCA2D2BAAFCQ34354215-4B5BBA8A-3CF3-4577-91F5-8CC9AFFC53E8Q34545841-74C6CFD6-959C-4142-8270-2662F04FBA18Q34702338-0CD9D0ED-E074-4636-BDEE-3B03D3C07F17
P2860
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@ast
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@en
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@nl
type
label
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@ast
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@en
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@nl
prefLabel
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@ast
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@en
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@nl
P2093
P356
P1476
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.
@en
P2093
L Malspeis
M R Grever
R L Hickman
P304
P356
10.1007/S002800050328
P577
1995-01-01T00:00:00Z